Presented at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference, March 15–18, 2021 | Corresponding author: Perry B. Shieh; pshieh@mednet.ucla.edu

Casimersen Treatment in Eligible Patients with Duchenne Muscular Dystrophy: Safety, Tolerability, and Pharmacokinetics Over 144 Weeks of Treatment

Nancy L. Kuntz,[1] Kathryn R. Wagner,[2] Lilly East,[3] Sameer Upadhyay,[3] Baoguang Han,[3] Erica Koenig,[3] Perry B. Shieh,[4] on behalf of the Casimersen Study 4045-101 Clinical Investigators

[1]Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA; [2]Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA; [3]Sarepta Therapeutics, Inc., Cambridge, MA, USA; [4]Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA

Please scan QR code for full study details

Objective

To report safety, tolerability, and pharmacokinetics of casimersen in Study 4045-101 (NCT02530905) and interim dystrophin expression results from the Phase 3 ESSENCE study (NCT02500381)

Key Takeaway

Phase 1/2 and interim Phase 3 data support further evaluation of casimersen safety and efficacy in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping

CONCLUSIONS

- Casimersen 30 mg/kg was well tolerated in patients with DMD and confirmed mutations amenable to exon 45 skipping who had limited ambulation or were nonambulatory at baseline
- Most reported treatment-emergent adverse events (TEAEs) were mild in severity; 2 were related to treatment, and no patients discontinued study drug or reduced dosage due to TEAEs
- No clinically significant laboratory abnormalities or worsening in electrocardiograms and echocardiograms were noted
  - No suggestion of a significant risk of renal abnormality or renal toxicity with casimersen
- Pharmacokinetic profile suggests little to no plasma accumulation of casimersen following weekly dosing at 30 mg/kg
- Interim results from the ongoing ESSENCE study showed casimersen significantly increased exon 45 skipping and dystrophin protein expression
- Together, these results support further evaluation of casimersen safety and efficacy in patients with DMD amenable to exon 45 skipping

STUDY 4045-101 DESIGN AND PATIENTS

Multicenter, randomized, double-blind, placebo-controlled, dose-titration, Phase 1/2 study

Patients

- Males (7–21 years old) diagnosed with genotype-confirmed DMD amenable to exon 45 skipping
- Nonambulatory or incapable of walking ≥300 m on 6-minute walking test (6MWT)
- Mean baseline 6MWT distance: 39 m
- Patients randomized to casimersen were generally slightly older and had more advanced disease than those randomized to placebo
- 11 (92%) patients completed the study



Please scan QR code to view supplemental page for full study details and baseline demographics.
One participant prematurely discontinued study drug (received placebo during the double-blind period and casimersen during the open-label extension period); the reason for discontinuation was withdrawal by the patient after 143 weeks in the study.

RESULTS

Safety

- All patients experienced ≥1 TEAE; none discontinued or reduced dosage due to TEAEs
- Most TEAEs were mild in severity during the double-blind period (89%) and combined double-blind and open-label casimersen treatment periods (91%)
- Treatment-related TEAEs included 1 case of moderate iron deficiency and 1 case of mild flushing in 2 casimersen-treated patients
- 3 casimersen-treated patients experienced 5 serious AEs, which were considered not related to treatment and resolved during the study
- No evidence of renal toxicity
- No cardiac signals
- No patterns, trends, or abnormalities were observed in clinical laboratory parameters
- No deaths

Please scan QR code to view supplemental page for full safety details.

TEAEs reported during casimersen treatment in the combined double-blind and open-label periods in Study 4045-101

Patients, n (%)	Total (N=12)
≥1 TEAE	12 (100)
≥1 serious TEAE	3 (25.0)
≥1 TEAE related to treatment	2 (16.7)
TEAEs reported in ≥25% of patients	
Nasopharyngitis	9 (75.0)
Cough	4 (33.3)
Headache	4 (33.3)
Procedural pain	4 (33.3)
Upper respiratory tract infection	4 (33.3)
Vomiting	4 (33.3)
Nausea	3 (25.0)
Pain in extremity	3 (25.0)
Oropharyngeal pain	3 (25.0)
Rash	3 (25.0)
Tibia fracture	3 (25.0)
Total number of TEAEs by severity	
Mild	159
Moderate	14
Severe	2

Only TEAEs with an onset date after administration of the first dose of casimersen are included.

Plasma casimersen concentration over time by dose and week in Study 4045-101



All pharmacokinetic parameters were similar for casimersen 30 mg/kg/week at Weeks 7 and 60, suggesting little to no accumulation in plasma with weekly dosing

TEAEs reported in the double-blind period in Study 4045-101

Patients, n (%)	Placebo (n=4)	Casimersen 4 mg/kg (Weeks 1–2) (n=8)	Casimersen 10 mg/kg (Weeks 3–4) (n=8)	Casimersen 20 mg/kg (Weeks 5–6) (n=8)	Casimersen 30 mg/kg (Weeks 7–8) (n=8)	Casimersen 30 mg/kg (Week 7 to end of double-blind period) (n=8)	Total (n=8)
≥1 TEAE	4 (100)	5 (62.5)	3 (37.5)	3 (37.5)	4 (50.0)	7 (87.5)	8 (100)
≥1 serious TEAE	0	0	0	0	1 (12.5)	1 (12.5)	1 (12.5)
≥1 TEAE related to treatment	1 (25.0)	1 (12.5)	0	0	0	1 (12.5)	2 (25.0)
TEAEs reported in ≥25% of patients							
Procedural pain	1 (25.0)	0	0	2 (25.0)	2 (25.0)	3 (37.5)	4 (50.0)
Headache	0	1 (12.5)	0	0	1 (12.5)	2 (25.0)	3 (37.5)
Vomiting	0	0	0	2 (25.0)	1 (12.5)	2 (25.0)	3 (37.5)
Nausea	0	1 (12.5)	1 (12.5)	1 (12.5)	0	0	2 (25.0)
Nasopharyngitis	1 (25.0)	1 (12.5)	0	0	1 (12.5)	1 (12.5)	1 (12.5)
Pain in extremity	1 (25.0)	0	0	0	1 (12.5)	1 (12.5)	1 (12.5)
Skin papilloma	1 (25.0)	0	0	0	1 (12.5)	1 (12.5)	1 (12.5)
Contact dermatitis	2 (50.0)	0	0	0	0	0	0
Back pain	1 (25.0)	0	0	0	0	0	0
Ligament sprain	1 (25.0)	0	0	0	0	0	0
Oropharyngeal pain	1 (25.0)	0	0	0	0	0	0
Tinea versicolor	1 (25.0)	0	0	0	0	0	0
Total number of TEAEs by severity							
Mild	11	9	3	9	13	26	47
Moderate	0	0	0	1	1	3	4
Severe	0	0	0	0	2	2	2

Dystrophin protein expression in the ESSENCE study

- ESSENCE is an ongoing, 96-week, double-blind, placebo-controlled, Phase 3 study in ambulatory males aged 7–13 years with DMD and a confirmed genetic mutation amenable to exon 45 skipping
- Interim results show a significant increase in dystrophin protein from baseline to Week 48 in casimersen-treated patients ($P<0.001$)



Significant positive correlation between exon 45 skipping and dystrophin production was observed (Spearman rank correlation = 0.627, $P<0.001$)

Please scan QR code for full ESSENCE study details.

ACKNOWLEDGMENTS & DISCLOSURES

The authors and Sarepta Therapeutics, Inc., thank the patients and their families. Editorial support was provided by Valerie P. Zediak, of Eloquent Scientific Solutions, and was funded by Sarepta Therapeutics, Inc. **Disclosures: NLK** has served on advisory boards for Audentes, AveXis, Biogen, Cytokinetics, PTC Therapeutics, Roche, and Sarepta Therapeutics, Inc. **KRW** has served as a consultant for AskBio, Dynacure, PTC Therapeutics, Roche, and Sarepta Therapeutics, Inc., and serves on the DSMB for Fibrogen and on a dose escalation committee for Wave. Current affiliation is Roche. **PBS** has served as a consultant on ad hoc advisory boards for AveXis, Biogen, PTC Therapeutics, and Sarepta Therapeutics, Inc., and has served on speakers' bureaus for Alexion, Biogen, and Grifols. **LE, SU, BH, and EK** are employees of Sarepta Therapeutics, Inc., and may own stock/options in the company. Products are investigational only.
Presented previously at the World Muscle Society Virtual Congress, September 28 – October 2, 2020

BACKGROUND

- Duchenne muscular dystrophy (DMD) is a fatal, X-linked neuromuscular disease caused by mutations in the dystrophin (*DMD*) gene[1]; mutations leading to deletions flanking exon 45 account for 8% of all patients with DMD[2]
- Casimersen is designed to bind to exon 45 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing and allowing for production of an internally truncated dystrophin protein
- Study 4045-101 (NCT02530905) was a first-in-human, Phase 1/2, 2-part clinical trial designed to assess safety, tolerability, and pharmacokinetics of casimersen in patients with DMD with mutations amenable to exon 45 skipping who had limited ambulation or were nonambulatory
- ESSENCE (NCT02500381) is an ongoing, Phase 3, multicenter study in ambulatory patients with DMD amenable to exon 45 skipping or exon 53 skipping

STUDY 4045-101 DETAILS

METHODS

Study design and treatment

- During the double-blind dose-titration period, patients were randomized 2:1 to receive increasing doses of IV casimersen at ≥2-week intervals (4, 10, 20, and 30 mg/kg/week) or placebo, for 12 weeks
- Subsequently, all patients received casimersen 30 mg/kg in an open-label extension period for up to 132 weeks
- Patient inclusion criteria
  - —Males aged 7–21 years with DMD and a confirmed genetic mutation amenable to exon 45 skipping
  - —Stable cardiac and pulmonary function
  - —On a stable dose or had not received oral corticosteroids for ≥24 weeks prior to study initiation
  - —Nonambulatory or unable to walk ≥300 m on the 6MWT

RESULTS

Study population

- Of 12 patients enrolled, 11 (91.7%) completed Study 4045-101
- Mean (SD) total time on study was 144.7 (3.45) weeks and total casimersen treatment was 139.6 (9.26) weeks

Baseline characteristics of patients in Study 4045-101[a]

Parameter	Placebo (n=4)	Casimersen (n=8)	Total (N=12)
Age, years	12.0 (2.2)	14.4 (3.3)	13.6 (3.1)
Race, n (%)			
White	4 (100)	6 (75.0)	10 (83.3)
Asian	0	2 (25.0)	2 (16.7)
Ethnicity, n (%)			
Hispanic or Latino	0	1 (12.5)	1 (8.3)
Not Hispanic or Latino	4 (100)	7 (87.5)	11 (91.7)
BMI, kg/m^2	21.9 (1.2)	25.9 (4.8)	24.6 (4.3)
6MWT distance,[b] m	115.4 (134.2)	0.9 (2.5)	39.1 (90.0)
Time since DMD diagnosis, months	91.8 (33.7)	136.1 (47.9)	121.3 (47.4)
Duration of corticosteroid use, months	84.5 (38.3)	80.1 (34.5)	81.6 (34.1)

BMI=body mass index. Values are mean (SD) unless noted otherwise. [a]Baseline was defined as the last value prior to the first dose of study drug. [b]Patients who were not ambulatory were considered to have a 6MWT distance of 0 m.

Safety

- Procedural pain and nasopharyngitis were the most commonly reported TEAEs during the double-blind and combined casimersen treatment periods, respectively
- AEs and laboratory results showed no evidence of renal toxicity and no suggestion of a significant risk of renal abnormality with casimersen
- Treatment-related TEAEs included 1 case of moderate iron deficiency and 1 case of mild flushing in 2 casimersen-treated patients, and mild contact dermatitis in 1 patient who received placebo
  - — Casimersen-related TEAEs resolved during the study; the placebo-related TEAE was ongoing at end of study
- 5 serious TEAEs occurred in 3 patients receiving casimersen 30 mg/kg during the combined treatment periods
  - — Bacteremia, septic embolus, and vena cava thrombosis in 1 patient were related to a venous port placed for casimersen administration
  - — 2 patients experienced bone fracture (tibia or femur)
  - — All 5 events were considered not related to casimersen, resolved during the study, and did not recur with further dosing
- No patterns, trends, or abnormalities were observed in hematology, coagulopathy, chemistry, or other clinical laboratory parameters
- No cardiac signal was noted in conduction time or functional assessment by echocardiogram
  - — One case of transient ventricular tachycardia was reported, but the event was considered unrelated to casimersen treatment and the electrocardiogram normalized without sequelae

Pharmacokinetics

- Pharmacokinetic analyses suggest casimersen exposure is approximately dose proportional within the tested range of 4–30 mg/kg
- Mean casimersen half-life ranged from 2.9–3.8 hours

ESSENCE STUDY DETAILS

Study design

- ESSENCE is an ongoing, 96-week, double-blind, placebo-controlled, Phase 3 study with a subsequent 48-week open-label period
- Patients are randomized 2:1 to casimersen 30 mg/kg once weekly or placebo
- Patient inclusion criteria
  - – Males aged 7–13 years with DMD and a confirmed genetic mutation amenable to exon 45 skipping
  - – 6MWT distance ≥300 and ≤450 m
  - – Stable pulmonary function, percent predicted forced vital capacity (FVC%p) >50%
  - – On a stable dose of oral corticosteroids for ≥6 months

Dystrophin expression

- Interim results show change from baseline was greater in the casimersen arm compared with the placebo arm (P=0.004)
- Of the 27 patients receiving casimersen, all displayed an increase in exon 45 skipping (P<0.001) vs baseline, representing a 100% response rate (data not shown)

Presented at the 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference, March 15–18, 2021
Corresponding author: Perry B. Shieh; pshieh@mednet.ucla.edu

REFERENCES
1. Birnkrant DJ, et al. *Lancet Neurol*. 2018;17:251-67. 2. Aartsma-Rus A, et al. *Hum Mutat*. 2009;30:293-9.